We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Under conservative assumptions, our estimates imply that the average annual increase in life expectancy of the entire population resulting from new drug launches is about one week, and that the incremental cost effectiveness ratio (new drug expenditure per person per year divided by the increase in life-years per person per year attributable to new drug launches) is about $6750-far lower than most estimates of the value of a statistical life-year.
. Life expectancy at birth, world. brought about by improvements in information technology, not pills and scalpels (Getzen (1997:330) ).
Research on the relationship between health status and medical care frequently has found that the marginal contribution of medical care to health status is rather small. . . any significant improvements in health status are more likely to originate from factors other than medical care. . . Factors that determine the level of health include income and education, environmental and life-style factors, and genetics (Henderson (1999:142) ).
The historical declines in population mortality rates were not due to medical interventions because effective medical interventions became available to populations largely after the mortality had declined. Instead, public health, improved environment, and improved nutrition probably played substantial roles (Folland, Goodman and Stano (2001:118) ).
But some recent research has indicated that technological innovations in medicine have had important positive impacts on health. Cutler and McClellan (2001) reviewed case studies of technological change in the treatment of five conditions (heart attack, lowbirthweight infants, depression, cataracts, and breast cancer) in the U.S. They concluded that "in most of the cases we analyzed, technological innovations in medicine are on net positive. Technology often leads to more spending, but outcomes improve by even more" (p. 23) .
In this paper, we will perform an econometric analysis of the effect of new drug launches on longevity. Bresnahan and Gordon (1997) argue that "new goods are at the heart of economic progress." Investment in research and development (R&D) is a prerequisite for new good development, and the pharmaceutical industry is the most research-intensive industry in the economy. Drugs are much more research-intensive than most other goods and services utilized in the health care sector. As the data in the following table show, 2 in the U.S. in 1994 pharmaceutical industry R&D expenditure accounted for almost a third of total health R&D expenditure and more than half of industry health R&D expenditure. Moreover, according to the Global Forum for Health Research (2002) , the pharmaceutical industry accounted for 42% of global health R&D funded by advanced and transition countries in 1998.
Clinical studies of specific drugs have shown that these drugs increase longevity. Here are three examples:
• Stenestrand et al. (2001) studied the impact on survival of statin treatment following acute myocardial infarction. They found that 1-year mortality was 9.3% in the no-statin group and 4.0% in the statin treatment group. • Grier et al. (2003) found that adding two experimental drugs to the standard four-drug chemotherapy regimen has significantly improved survival in patients with non-metastatic Ewing's sarcoma, a highly malignant bone cancer of children and young adults. The overall survival rate increased from 61 percent to 72 percent for Ewing's sarcoma patients with localized disease who underwent the experimental six-drug chemotherapy.
• The journal U.S. Pharmacist (2002) reported that patients suffering from advanced metastatic melanoma who were treated with a combination of an investigational agent, Ceplene, and interleukin-2 (IL-2) had twice the survival rate as patients who were treated with IL-2 only. The patients were enrolled in a three-year study. The study also showed that the Ceplene/IL-2 combination significantly increased survival in a subpopulation group of advanced metastatic melanoma patients with liver metastases. The rate of survival in this group was six times that of the group given IL-2 only.
My objective is to assess the average or aggregate contribution of all new drug introductions. The data we will analyze cover all of the drugs introduced in, and diseases borne by people in, 52 countries during the period 1982-2001. Fortunately, launches of new drugs in these countries have been carefully tracked since 1982 by IMS Health. 3 Moreover, we can determine the (primary) disease associated with each new drug. Hence, we can measure the entry of new drugs, by disease, country, and year. Using data from the World Health Organization, we can also measure mortality (the age distribution of deaths) by disease, country, and year. Analysis of the relationship between new drug launches and mortality using longitudinal, disease-level data from 52 countries enables us to control, to an unusually great extent, for the effects of other potential determinants of mortality, e.g. education, income, nutrition, the environment, and "lifestyle".
The remainder of this paper is organized as follows. Section 1 outlines an econometric framework. Measurement issues and data sources are discussed in Section 2. Empirical results are presented in Section 3. Implications of the estimates are discussed in Section 4. Section 5 contains a summary.
Econometric Framework
We hypothesize that the age distribution of deaths from disease i in country j in year t depends on the cumulative number of drugs launched to treat disease i in country j by year t − k, and on other factors:
where AGE DEATH i jt = a statistic based on the age distribution of deaths from disease i in country j in year t N DRUG i j,t−k = the cumulative number of drugs launched to treat disease i in country j by year t − k X i jt = a vector of other factors (e.g. education, income, nutrition, the environment, and "lifestyle") affecting the age distribution of deaths from disease i in country j in year t Equation (1) may be viewed as a health production function. AGE DEATH is an indicator of "health output". N DRUG may be viewed as an indicator of the level of medical technology. 4 We specify AGE DEATH to be a function of the logarithm of N DRUG because we hypothesize that there are diminishing returns to additions to the stock of drugs. In principle, it would be desirable to distinguish between the effects of drugs that provide substantial therapeutic advantages over existing drugs and the effects of other, less significant drugs. Drugs launched in the U.S. can be classified into these two categories, since the U.S. Food and Drug Administration designates drugs as either "priority-review" drugs or "standard-review" drugs. However, this classification is undoubtedly subject to error-it is made prior to the drug's review by the FDA-and it does not apply to drugs not launched in the U.S.
We specify a k-year lag in the relationship to allow for gradual diffusion of new drugs to consumers; we will estimate the model using different assumed values of k (k = 0, 1, 2, . . .). The following data on the U.S. sales rank of two major drugs launched in the mid 1990s suggest the nature of the lag structure.
We hypothesize that many of the "other factors" (X i jt in Eq. (1)) affecting the age distribution of deaths from disease i in country j in year t (e.g. per capita income, public health expenditure, and environmental quality) are invariant across diseases within a country and year, invariant across countries within a disease and year, or invariant across years within a country and disease. For biological reasons, people tend to die at younger ages from some diseases than from others in a given year, in all countries. For economic and other reasons, people tend to die at younger ages in some countries than in others in a given year, from all diseases.
Without loss of generality, we can decompose X i jt as follows:
where α it = a fixed effect for disease i in year t δ jt = a fixed effect for country j in year t θ i j = a fixed effect for disease i in country j
Substituting (2) into (1),
where
For example, suppose, as previous authors have argued, that environmental quality is an important determinant of AGE DEATH, and also that environmental quality is correlated with N DRUG. If environmental quality is invariant across diseases within a country and year, then its effect on AGE DEATH is completely controlled for by δ jt . If environmental quality varies across diseases, but deviations from country-year means are constant over time, then its effect on AGE DEATH is completely controlled for by δ jt and θ i j . If environmental quality varies across diseases, and deviations from country-year means are not constant over time, estimates of β will be consistent as long as the deviation of environmental quality from its mean deviation from country-year means is uncorrelated with the deviation of ln(N DRUG i j,t−k ) from its mean deviation from country-year means. The same argument applies to other potential determinants of AGE DEATH (income, education, etc.).
While we can measure the stock of drugs by disease, country, and year, due to data limitations, we cannot measure the availability of medical devices (or of diagnostic and surgical procedures). If changes in the stock of devices are uncorrelated across diseases with changes in the stock of drugs, the drug-stock coefficient is unbiased. If changes in the stocks of devices and drugs are correlated (controlling for the fixed effects in Eq. (3)), the drug-stock coefficient could be biased. The direction of bias depends on the sign of the correlation. If the change in the stock of devices is negatively correlated across diseases with the change in the stock of drugs, the drug-stock coefficient is downward biased. Some evidence suggests that this correlation may indeed be negative. Lichtenberg (1996 Lichtenberg ( , 2001 presented evidence that use of newer drugs is associated with lower utilization of hospital care. Since use of some medical devices, such as stents and artificial hearts, requires hospitalization, drugs and devices may be substitutes rather than complements. Moreover, according to the Agency for Healthcare Research and Quality (2002) , in 1999 the number of Americans using prescription drugs (172 million) was over eight times as large as the number with any hospitalizations (20 million). 5 If pharmaceutical companies are more likely to launch drugs in product/geographic markets where they will have the largest impact on AGE DEATH, then Eq. (3) could result in an overestimate of the average longevity impact of new drug launches. While this possibility cannot be entirely ruled out, there are reasons to doubt substantial overestimation of the average longevity impact. First, previous studies of the determinants of drug launch have not found any evidence that pharmaceutical companies are more likely to launch drugs in product/geographic markets where they will have the largest impact on AGE DEATH: Danzon et al. (2003) and Kyle (2003) both found that market size (population) and the regulatory regime are important determinants of the probability of drug launch. 6 Second, if pharmaceutical firms tend to launch in markets where the benefit of launch is greatest, they are likely to launch in markets with the highest total, rather than average, longevity benefit. Suppose that the expected effect of a new leukemia drug on mean age at death in country A is 6 months, and that the expected effect in country B is 1 month. If 10 times as many people suffer from leukemia in country B as do in country A, then the social (and presumably private) benefits to launch in country B is higher, even though the benefit per patient is lower. Changes in AGE DEATH reflect the average, rather than total, longevity benefit. 
Measurement

Drug Launches
We used data from the IMS Health Drug Launches database 8 to construct estimates of the number of drugs launched to treat disease i in country j by year t − k. This database has tracked new product introductions worldwide since 1982. In August 2001 the database contained over 165,000 records of individual product introductions between 1982 and 2001. Seventy-two countries are covered; many have been tracked since 1982. Data on product introductions is gathered from the IMS Health network of offices around the world and reflects the information on the product at the time of launch into each country.
Each record in the database contains the following information: the date and country of product launch, the active ingredient(s) of the product, a dummy variable indicating whether the product's ingredient is a new chemical entity (i.e. whether no products containing this ingredient have been launched anywhere before), and the therapeutic class of the product. The IMS therapeutic classification is extremely detailed; we recoded (aggregated) therapeutic classes into 11 therapeutic areas (e.g. nervous system drugs, respiratory drugs).
We constructed a list of all of the ingredients occurring in the database. This list contained information about two ingredient attributes: (1) whether the ingredient was a new chemical entity (i.e. was not launched anywhere in the world before 1982), and (2) the therapeutic area most frequently associated with the ingredient. 9 We also constructed, for each country, a list of the active ingredients contained in products launched anytime during , and the first year in which that ingredient was observed in that country. We then merged the list of ingredients by country with the list of ingredient attributes. This enabled us to determine, for each country and therapeutic area, the total number of ingredients launched, and the number of new chemical entities launched.
The IMS Health Drug Launches database yields reliable estimates of the number of new (post-1981) drugs, but not of the number of old (pre-1982) drugs, or of the total (new + old) number of drugs. This is due to the fact that the launch data are right-censored: the IMS Health Drug Launches database does not cover products that were launched before 1982. Suppose that products launched in a country before 1982 contained a certain ingredient, but that no products launched since 1982 did. Provided that the products launched before 1982 are still on the market, that ingredient is still available to consumers, but we would not count it as an available ingredient. We can accurately measure the number of new drugs since, if an ingredient is identified by IMS as a new chemical entity, it could not have been launched prior to the initial launch date provided in the database.
If an ingredient is designated an NCE, then we can be confident that the date of the earliest observed launch of that ingredient in that country is the initial launch date. However, if an ingredient is not designated an NCE, then the date of the earliest observed launch of that ingredient in that country may not be the initial launch date-the ingredient may have been launched in that country prior to 1982. 10 In other words, NCE launches are guaranteed to be initial launches, but non-NCE launches may be either initial launches or re-launches; we suspect they are predominantly the latter.
To address the censoring problem, we will estimate two different models:
where CUM NCE = the cumulative number of NCEs launched CUM non-NCE = the cumulative number of non-NCEs launched
In Eq. (4a), AGE DEATH depends only on the cumulative number of NCEs launched, whereas in Eq. (4b), it depends on both the cumulative number of NCEs launched and the cumulative number of non-NCEs launched. We hypothesize that β NCE > β NON , i.e. that increases in the stock of NCEs increase AGE DEATH more than increases in the stock of NCEs. While one might expect β NON to be positive, or at least nonnegative, we can think of a reason why β NON might be negative. Our basic hypothesis is that the greater the proportion of people consuming NCEs, the higher mean age at death will be. It is plausible that the proportion of people consuming NCEs is positively related to the number of NCEs launched and negatively related to the number of non-NCEs launched. Suppose, for example, that β NON = −β NCE ; then Eq. (4b) reduces to
AGE DEATH depends on the ratio of NCEs to non-NCEs approved. The higher this ratio, the higher the probability that a person is consuming an NCE, as opposed to a non-NCE drug.
Age Distribution of Deaths
We obtained data on the age distribution of deaths, by disease, country, and year, from the World Health Organization (WHO) Mortality Database. 11 These data enable us to compute the fraction of deaths that occur above (or probability of survival until) certain ages, such as 55 and 65 years of age.
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We wish to provide estimates of the impact of new drug launches on life expectancy (at various ages, and for the population overall), as well as on survival probabilities. While complete life tables (which include life expectancies and survival probabilities) are available at the country level for various years, there are no disease-specific life tables, e.g. there are no published data on life expectancy of people with heart disease. However, we believe we can use aggregate life tables to translate our estimates of the impact of new drug launches on survival probabilities into estimates of the impact of new drug launches on life expectancy.
We obtained two different samples of country-level life tables: a time-series of decennial life tables for the U.S. for the period 1900-2000, and a cross-section of life tables for 191 countries in the year 2000. Each life table contains the following variables: life expectancy (years of remaining life) at age a (LE a , a = 0, 5, 10, . . . , 100), and the probability of survival from birth until age 65 (SURV65). The data suggest that SURV65 is a fairly good "sufficient statistic" for characterizing changes or differences in life expectancy. This is illustrated by Figure 3 , which graphs life expectancy at two different ages (birth and age 30) against SURV65, using data from the 11 decennial U.S. life tables during the period 1900-2000. The R 2 of the regression of life expectancy at age 30 (LE 30 ) on SURV65 is .974, and the slope is 30.9, indicating that a .01 increase in SURV65 is associated with a 0.31-year increase in LE 30 . The R 2 of the regression of life expectancy at birth (LE 0 ) on SURV65 is even higher (.997), and the slope is 66.0, indicating that a .01 increase in SURV65 is associated with a 0.66-year increase in LE 0 . We computed the regressions of life expectancy at each age (LE a , a = 0, 5, 10, . . . , 100) on SURV65, using both the time-series U.S. sample of life tables, and the cross-sectional international sample. The regression coefficients are plotted in Figure 4 . The estimates yielded by the two samples are fairly consistent with one another. For example, the slopes of the age-0 U.S. and international regressions are 66.0 and 60.3, respectively, and the slopes of the age-30 regressions are 30.9 and 34.3, respectively.
Suppose that we estimate Eq. (4a), where AGE DEATH i jt is defined as PCT GT65 i jtthe percent of deaths from disease i in country j in year t that occurred above the age of 65. PCT GT65 is presumably a reasonable estimate of SURV65. Hence β NCE ≈ δ SURV65/δ ln(CUM NCE). To estimate δ LE a /δ ln(CUM NCE), we simply multiply β NCE by the regression coefficient shown in Figure 4 . For example, using the U.S. estimate, δ LE 0 /δ ln(CUM NCE) = 66.0 * β NCE .
In addition to estimating the impact of new drug launches on life expectancy at given ages, we can estimate the impact on the overall life expectancy of the population(LE POP ), 13 by calculating the weighted average of the regression coefficients shown in Figure 4 , weighting by the share of the population in each age group. The resulting life-expectancy multipliers are as follows 14 : Figure 4 . Coefficients from regressions of life expectancy at age a on probability of survival to age 65.
To convert an estimate of the effect of a change in ln(CUM NCE) on SURV65 to an estimate of its effect on life expectancy of the overall population, simply multiply by 33!
Linkage of Drug Launches to Diseases
The drug launches documented in the IMS Health Drug Launches database are classified by therapeutic category. The classification system used by IMS is very detailed, but hierarchical. At the lowest (most detailed) level, there are more than 500 therapeutic classifications, e.g. prostaglandin antiulcerants (A2B3), and ACE inhibitor combinations with calcium antagonists (C9B3). At the highest level, there are 16 categories, e.g. Alimentary Tract And Metabolism (A), and Cardiovascular System (C).
The deaths documented in the WHO Mortality Database are classified by cause (disease), using the International Classification of Diseases (ICD). 15 Like the drug classification system, the ICD is very detailed, but hierarchical. At the highest level, there are 17 disease categories, e.g. Neoplasms (ICD10 codes C00-D48) and Diseases of the circulatory system (I00-I99).
The high-level IMS drug classification corresponds quite closely to the high-level ICD disease classification. 16 For example, cardiovascular system drugs obviously correspond to (are used to treat) diseases of the circulatory system. We defined 11 broad disease categories, and classified drug launches and deaths into these categories as follows: 
Descriptive Statistics
The IMS Health Drug Launches data indicate that 864 NCEs were introduced worldwide during 1982-2001. Figure 5 shows the number of NCEs introduced in each year. The annual number ranged from 34 to 59. Figure 6 shows the distribution of NCEs launched, by principal therapeutic class. The four largest classes account for 54% of all NCEs launched. As shown in Figure 7 , the distribution of deaths, by cause (each cause corresponds to a therapeutic class), is much more skewed. One cause-circulatory diseases-accounts for almost half (48%) of all deaths. The next three largest causes are neoplasms (27%), respiratory diseases (10%), and digestive/endocrine/nutritional/metabolic diseases (8%). The four largest causes account for 93% of deaths. Table 1 shows the number of NCEs launched, by country, for countries covered in the database from 1982 to at least 2001. The three countries with the largest number of NCE launches (over 400) were Italy, Japan, and the U.S. Even in these countries, fewer than half of NCEs launched worldwide were launched. In six of the 40 countries-Malaysia, Egypt, Saudi Arabia, Singapore, Pakistan, and Indonesia-fewer than 200 NCEs were launched. Table 2 shows the number of deaths, and the percent of deaths at age greater than or equal to 65, by country, in the most recent year for which mortality data for that country were available.
Empirical Results
Estimates of Eqs. (4a) and (4b), which explain the international variation in changes in the relative survival rates of different diseases ("difference in differences of differences"), are shown in Table 3 . Estimates of β NCE that are negative and significant signify that aboveaverage increases in the relative number of NCEs launched to treat a disease in a country are associated with above-average increases in relative survival from that disease in that country. For example, between 1986 and 1991, four NCES for cancer were launched in Australia, increasing the stock from 7 NCEs to11 NCEs. This was an unusually large increase in the stock, in view of the number of cancer NCEs launched worldwide and the total number of launches in Australia (for all diseases) during that period. Therefore, one would expect the cancer survival rate to have increased at an unusually high rate in Australia during 1986-1991, relative to the overall increase in Australian longevity and the global increase in cancer survival rates during that period. But between 1991 and 1999, the percentage increase in the Australian stock of cancer drugs was smaller than expected, in light of the number of cancer NCEs launched worldwide and the total number of launches in Australia (for all diseases) during that period. The stock increased 191%, from 11 to 32, whereas the expected increase in the stock was 458% (from 7.4 to 41.2 NCEs). Consequently, one would expect the cancer survival rate to have increased at a below-average rate in Australia during 1991-1999, relative to the overall increase in Australian longevity and the global increase in cancer survival rates during that period. The dependent variable in all equations in Table 3 is the fraction of deaths that occurred at age 65 and over. 17 We chose this variable in part because it was the most widely available statistic in the WHO Mortality Database. All equations were estimated using data on 11 diseases in 52 countries over a maximum of 20 years (1982-2001) . All equations included complete sets of country * year, disease * year, and country * disease interaction effects. For example, the zero-lag equation (k = 0), which was estimated using 4678 observations, included 496 country * year effects, 189 disease * year effects, and 502 country * disease effects. The equations were estimated via weighted least squares, using the number of deaths in that disease-country-year cell as the weight.
The first column of Table 3 shows the regression of AGE DEATH i jt on ln(CUM NCE i jt ), i.e. a regression on the contemporaneous stock of NCEs, without controlling for the stock of non-NCEs. The estimate of β NCE is positive and statistically significant, which is consistent with the hypothesis that NCE launches increase longevity. The second column of the The dependent variable in all equations is the fraction of deaths that occurred at age 65 and over. All equations were estimated using data on 11 diseases in 52 countries over a maximum of 20 years (1982-2001) . All equations included complete sets of country * year, disease * year, and country * disease interaction effects. For example, the zero-lag equation (k = 0), which was estimated using 4678 observations, included 496 country * year effects, 189 disease * year effects, and 502 country * disease effects. The equations were estimated via weighted least squares, using the number of deaths in that disease-country-year cell as the weight.
table shows the regression of AGE DEATH i jt on both ln(CUM NCE i jt ) and ln(CUM non-NCE i jt ). Controlling for the stock of non-NCEs has very little impact on the estimate of β NCE . The estimate of β NON is negative and marginally significant, suggesting that, conditional on the cumulative number of NCE launches, the greater the cumulative number of non-NCE launches, the lower the probability of survival to age 65. This is consistent with the view that increasing the ratio of non-NCE to NCE launches reduces the fraction of people consuming NCEs, which in turn reduces longevity. The difference (β NCE − β NON ) is positive and significant. The remaining columns of Table 3 present regressions that are similar, except the regressors are lagged, rather than contemporaneous, values of the stocks of NCEs and non-NCEs. The third column of Table 3 shows the regression of AGE DEATH i jt on ln(CUM NCE i j,t−1 ), i.e. a regression on the stock of NCEs in the previous year, without controlling for the stock of non-NCEs. The estimate of β NCE is about 50% larger than it is in column 1, suggesting that longevity is more closely related to the lagged stock of NCEs than it is to the contemporaneous stock, presumably due to gradual diffusion of NCEs following launch. The fourth column of the table shows the regression of AGE DEATH i jt on both ln(CUM NCE i j,t−1 ) and ln(CUM non-NCE i j,t−1 ). As before, controlling for the stock of non-NCEs has very little impact on the estimate of β NCE . The estimate of β NON is also about 50% larger than it is in column 2, as is the estimate of the difference (β NCE − β NON ).
The fifth column of Table 3 shows the regression of AGE DEATH i jt on ln (CUM NCE i j,t−2 ), i.e. a regression on the stock of NCEs two years earlier, without controlling for the stock of non-NCEs. Once again, the estimate (and t-statistic) of β NCE increases by about 50%. The sixth column of the table shows the regression of AGE DEATH i jt on both ln(CUM NCE i j,t−2 ) and ln(CUM non-NCE i j,t−2 ). The estimate of β NON is slightly smaller, and less significant, than it was in column 4.
The remaining columns of Table 3 show estimates of the model for higher (3-to 6-year) lags between the stock of drugs launched and the age-65 survival probability. The estimate of β NON is not significantly different from zero when the lag is 3 or more years. 18 As summarized in Figure 8 , the estimate of β NCE increases as the lag increases from 0 to 3 years, and then levels off. This suggests that it takes three years for new NCE launches to have their maximum impact on survival rates. We hypothesize that this is due to the gradual diffusion of drugs to consumers following launch.
If NCEs diffuse gradually following launch, this might be reflected in pharmaceutical expenditure behavior. An increase in the stock of NCEs is likely to result in an increase in per capita pharmaceutical expenditure, via both increased utilization and higher prices. From the OECD Health Database, we obtained data, by country and year, on per capita pharmaceutical expenditure, expressed in U.S. dollars, evaluated at PPP (Rx expend). 19 After linking these data to the IMS Health Drug Launches data, we estimated the following equation for different values of k (k = 0, 1, 2, . . . , 6): Figure 8 . Estimates of β NCE for different lags between stock of NCEs launched and longevity.
The estimates are shown in the following For k ≤ 2, β expend is not significantly different from zero. This suggests that increases in the stock of NCEs have no impact on per capita pharmaceutical expenditure within two years. However, for 3 ≤ k ≤ 5, β expend is positive and statistically significant: increases in the stock of NCEs increase per capita pharmaceutical expenditure after three years. These results seem consistent with the time profile of the estimated effect of β NCE (the impact of the NCE stock on survival probability). Estimates of β NCE and β expend at different lag values are plotted in Figure 9 . It takes three to five years for an increase in the stock of NCEs to have its full impact on both pharmaceutical expenditure and survival rates.
Implications of the Estimates
Our estimates can be used to provide answers to several important questions:
• How much of the cross-country variation in longevity in a given year (e.g., 2000) is explained by international variation in the stock of NCEs launched since 1982? Figure 9 . Estimates of β NCE and β expend at different lag values.
• How much of the long-run increase in longevity in the sample as a whole is due to the launch of NCEs? • What is the cost per life-year gained from the launch of NCEs?
The last two questions can be answered under two alternative assumptions: (1) the estimates reflect the effect on longevity of new drug launches per se; and (2) the estimates reflect the effect of medical innovation in general.
To answer these questions, we will use the estimate of β NCE from column 9 of Table 3 , i.e. we will assume that ( PCT GT65 i jt / ln(CUM NCE i j,t−4 )) = .0065. Recall that this estimate controls for all other factors affecting PCT GT65 that are invariant across diseases within a country and year, invariant across countries within a disease and year, or invariant across years within a country and disease. Also, if we use aggregate life tables to translate our estimates of the impact of new drug launches on survival probabilities into estimates of the impact of new drug launches on life expectancy, as described above, then the effect of NCE launches on life expectancy at birth (LE 0 ) can be approximated by (63.2 * .0065) = 0.4105, and the effect of NCE launches on average life expectancy of the entire population (LE POP ) can be approximated by (33.0 * .0065) = .2145.
Cross-Sectional Differences
Heterogeneity with respect to NCE launches appears to explains very little of the international variation in longevity. 20 As shown in Table 1 
Time-Series Differences
In contrast, NCE launches appear to account for a significant fraction of the long-run increase in longevity in the sample as a whole. To measure this contribution, we adopted the following procedure. First, we inferred the average growth of PCT GT65 from estimates of the year effects (δ t 's) from the following equation: δ 1986 ) is an estimate of the change in the survival rate (and 33.0 * (δ t − δ 1986 ) is an estimate of the change in LE POP ) between 1986 and year t (t = 1987, 1988, . . . , 2000) , controlling for country * disease effects. Second, we inferred the average rate of growth of CUM NCE from estimates of the year effects (λ t 's) from the following equation 22 : λ 1986 ) is an estimate of the change in the log of the stock of NCEs between 1986 and year t, controlling for country * disease effects. Finally, the contribution of NCE launches to the increase in survival rates between 1986 and year t is equal to (.0065* (λ t − λ 1986 )), and the contribution of NCE launches to the increase in LE POP is equal to (33.0 * .0065 * (λ t − λ 1986 )). These calculations are summarized in Figure 10 . Between 1986 and 2000, average life expectancy of the entire population increased by almost two (1.96) years. (The fraction of deaths that occurred at or above age 65 increased by 6 percentage points.) Our estimates imply that NCE launches accounted for 0.79 years (40%) of the 1986-2000 increase in longevity. The average annual increase in life expectancy of the entire population resulting from NCE launches is .056 years (= 0.79/14), or 2.93 weeks.
These results suggest that launch delays reduce longevity. Suppose that drugs tend to be launched much later in country B than they are in country A, so that country B's stock of drugs today is the same as country A's stock 5 years ago. The estimates imply that this launch delay reduces the average longevity of the entire population in country B by about 15 weeks. Danzon, Wang and Wang (2002) present evidence that countries with lower prices or smaller market size experience longer delays in access to new drugs.
Cost per Life-Year Gained from the Launch of NCEs
The cost per life-year gained from the launch of NCEs appears to be extremely low. OECD data indicate that in 1997, average per capita pharmaceutical expenditure in OECD countries was about $250. The average annual increase in life expectancy of the entire population resulting from NCE launches is .056 years. The ratio of these two numbers-pharmaceutical expenditure per person per year divided by the increase in life-years per person per year attributable to NCE launches-is about $4500. 23 This is far lower than most estimates of the value of a U.S. life-year (Nordhaus, 2003; Murphy and Topel, 2003) . 24 Moreover, since the numerator includes expenditure on old drugs as well as on recently-launched NCEs, it probably grossly overstates the cost per life-year gained from the launch of NCEs. Data from the U.S. Medical Expenditure Panel Survey indicate that expenditure on "new drugs"-drugs that are less than 18 years old-accounts for approximately half of total drug expenditure. 25 This implies that the incremental cost effectiveness ratio-expenditure per person per year on new drugs divided by the increase in life-years per person per year attributable to NCE launches-is about $2250.
Effect of NCE Launches vs. Effect of Medical Innovation in General
As discussed above, due to our inability to measure the introduction of non-pharmaceutical medical innovations, these calculations might overstate the effect of new drug launches per se on life expectancy. Suppose that the estimated effect of new drug launches is capturing the effect of (country-disease-year-specific) medical innovation in general (the joint effect of new drugs, devices, and procedures) on longevity. Also, suppose that Effect on LE of new drug launches Effect on LE of all medical innovation = Pharmaceutical R&D expenditure Total health R&D expenditure
As discussed in the introduction, U.S. pharmaceutical R&D expenditure accounts for about 1/3 of national (private + public) health R&D expenditure, and about 60% of industry health R&D expenditure. If only 1/3 of the estimated effect of new drug launches on longevity is attributable to new drugs (and the remaining 2/3 is attributable to other medical innovations), then new drug launches have increased longevity by about one week per year-about 13% of total longevity increase-and the incremental cost effectiveness ratio is about $6750.
Summary
Until recently, there appears to have been a consensus among health economists (or at least authors of health economics textbooks) that the contribution of medical care to longevity increase and other health improvements has been quite modest. But some recent research has indicated that technological innovations in medicine have had important positive impacts on health.
In this paper, we have performed an econometric analysis of the effect of new drug launches on longevity. Drugs are much more research-intensive than most other goods and services utilized in the health care sector, so new drug introductions account for a substantial fraction of medical innovations.
Our sample included data on virtually all of the diseases borne by people in 52 countries during the period 1982-2001. Analysis of the relationship between new drug launches and longevity using these data enabled us to control, to an unusually great extent, for the effects of other potential determinants of longevity, e.g. education, income, nutrition, the environment, and "lifestyle".
We used data from the IMS Health Drug Launches database to construct estimates of the number of drugs launched to treat eleven different diseases in each country in each year. This database has tracked new product introductions worldwide since 1982, and contained over 165,000 records of individual product introductions. We obtained data on the age distribution of deaths, by disease, country, and year, from the World Health Organization (WHO) Mortality Database. These data enabled us to compute the fraction of deaths that occur above (or probability of survival until) certain ages, such as 55 and 65 years of age.
We found that launches of New Chemical Entities (NCEs) have a strong positive impact on the probability of survival. The estimates indicated that it takes at least three years for new NCE launches to have their maximum impact on survival rates. This is probably due to the gradual diffusion of drugs to consumers following launch; data on pharmaceutical expenditure were consistent with this interpretation.
Launches of (older) drugs that are not NCEs-many of which may already have been on the market-do not increase longevity. Indeed, some estimates indicated that, conditional on the cumulative number of NCE launches, the greater the cumulative number of non-NCE launches, the lower the probability of survival to age 65. This is consistent with the view that increasing the ratio of non-NCE to NCE launches reduces the fraction of people consuming NCEs, which in turn reduces longevity.
Heterogeneity with respect to NCE launches appears to explains very little of the international variation in longevity. But NCE launches appear to account for a significant fraction of the long-run increase in longevity in the sample as a whole. Between 1986 and 2000, average life expectancy of the entire population of sample countries increased by almost two (1.96) years. If we assume that our estimates reflect the effect on life expectancy of new drug launches per se, we may conclude that NCE launches accounted for 0.79 years (40%) of the 1986-2000 increase in longevity. The average annual increase in life expectancy of the entire population resulting from NCE launches is .056 years, or 2.93 weeks, and the incremental cost effectiveness ratio-expenditure per person per year on new drugs divided by the increase in life-years per person per year attributable to NCE launches-is about $2250. Previous authors have shown that countries with lower prices or smaller market size experience longer delays in access to new drugs; our results imply that launch delays reduce longevity.
It is possible that our estimates reflect the effect on life expectancy of medical innovation in general-new medical devices and procedures, as well as new drugs-although some evidence suggests that new drugs and other medical innovations are substitutes, rather than complements. If we assume that only one-third of the estimated effect of NCE launches is attributable to new drugs per se (pharmaceutical R&D accounts for about one-third of total health R&D), then we may conclude that new drug launches accounted for 13% of the 1986-2000 increase in longevity; that the average annual increase in life expectancy of the entire population resulting from these launches is about one week; and that the incremental cost effectiveness ratio is about $6750. Even this figure is far lower than most estimates of the value of a statistical life-year.
Notes
